Study Evaluating SKI-606 Administered to Healthy Subjects

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: November 29, 2006
Last updated: December 3, 2007
Last verified: December 2007
Safety and tolerability of SKI-606 in healthy subjects; the influence of food intake on the same.

Condition Intervention Phase
Drug: SKI-606
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Pharmacokinetics; safety and tolerability; influence of food.

Study Start Date: November 2006
Study Completion Date: August 2007

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00406406

Utrecht, Netherlands, 3584 CJ
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Netherlands,
  More Information Identifier: NCT00406406     History of Changes
Other Study ID Numbers: 3160A1-103 
Study First Received: November 29, 2006
Last Updated: December 3, 2007
Health Authority: Netherlands: Medical Ethics Review Committee (METC) processed this record on May 23, 2016